The FDA has approved iCAD’s Xoft Axxent electronic brachytherapy system, which delivers high dose rate brachytherapy for intracavitary treatment of cancer of the uterus, cervix, endometrium and vagina.

Xoft’s cervical applicator is designed to treat locally advanced stage cervical cancer in combination with the Xoft System by delivering the prescribed radiation dose to the uterus, and cervix, endometrium and vagina with reduced radiation exposure to the surrounding healthy tissue, according to Nashua, N.H.-based iCAD.  

The Xoft system is a mobile, isotope-free alternative to radionuclide-based high-dose radiation brachytherapy, the company said in a press release.  

Xoft also recently received FDA clearance for an upgraded Xoft system controller capability that will support the cervical applicator and offer enhanced platform features.